BriaCell Therapeutics Corp. (BCTX)
NASDAQ
Closed
Aug 24, 2026
Day's Range
3.4552 wk Range
2.60Overview - BCTX - BriaCell Therapeutics Corp.
Key Statistics
Valuation
Enterprise Value
11.95M
P/E (Trailing)
‪-0.05‬
P/E (Forward)
‪-9.46‬
PEG Ratio
‪0.00058‬
Price / Book
‪1.11‬
EV / EBITDA
‪-0.37‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-90.84%‬
Return on Equity
‪-175.25%‬
Ownership
Shares Outstanding
7.25M
Float
7.85M
Short % of Shares Outstanding
‪4.70%‬
Held by Insiders
‪0.50%‬
Held by Institutions
‪6.39%‬
Price stats
Beta
‪1.51‬
50-Day Avg
‪3.43‬
200-Day Avg
‪5.12‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BCTX - BriaCell Therapeutics Corp.
Peers - BCTX - BriaCell Therapeutics Corp.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BCTXNASDAQBriaCell Therapeutics Corp.35.40MMarket Cap-84.03%52-week change-0.07P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.84BMarket Cap+39.72%52-week change-21.44P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - BCTX - BriaCell Therapeutics Corp.
About
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in developing novel immunotherapies to transform cancer care. The company focuses on cell-based cancer immunotherapies designed to harness and direct the immune system against tumors, with initial emphasis on metastatic breast cancer…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
